Evidence map›Paper›PMID 42318197›Full record

ReviewFrontiers in neuroscience2026

Ethanol exposure and high-fat diet: assessing the neuroimmune and metabolic mechanisms in Alzheimer's disease pathology.

George Chigozie Njoku, Viswanathan Saraswathi

Abstract readReview
In one paragraph

Review in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

George Chigozie NjokuDepartment of Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, NE, United States.
Viswanathan SaraswathiDepartment of Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, NE, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a chronic, progressive neurodegenerative disorder characterized by the accumulation of amyloid-β (Aβ) plaques and hyperphosphorylated Tau, leading to neurofibrillary tangle formation and synaptic dysfunction. Increasing evidence indicates that these hallmark pathologies are shaped by sustained alterations in neuroimmune and metabolic homeostasis. Lifestyle-associated exposures, including ethanol consumption and high-fat diet (HFD) intake, are emerging as modulators of neuroinflammatory tone and may influence susceptibility to AD-like pathology across the lifespan. Preclinical studies show that ethanol exposure increases Aβ42/40 ratios, promotes oxidative stress, and activates Tau-associated kinases, whereas HFD induces insulin resistance, alters microglial lipid handling, and impairs Aβ clearance. These effects converge on overlapping pathways involving microglial activation, metabolic dysregulation, and kinase-phosphatase imbalance. Evidence directly examining combined ethanol and HFD exposure remains limited; however, available studies suggest co-occurring or additive effects on cognitive impairment, neuroinflammation, and synaptic dysfunction. This review synthesizes current evidence to delineate shared neuroimmune and metabolic mechanisms linking ethanol and HFD exposure to AD-related pathology. We highlight points of mechanistic overlap, including oxidative stress, inflammatory signaling, and disrupted proteostasis, while distinguishing between directly measured effects and inferred pathways. Finally, we identify key gaps in understanding how dual exposures interact and outline priorities for future studies aimed at clarifying their contribution to AD risk and progression.

Indexed as

Alzheimer’s diseaseAβ clearanceethanolhigh-fat dietneuroinflammationTau

Identifiers

PMID42318197
PMCPMC13271955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.